The International Biomedical Research Alliance, in collaboration with the Lasker Foundation, invited six doctoral candidate students from the NIH Oxford-Cambridge/Wellcome Trust Scholars Program to attend the 2019 Lasker Awards in New York City.
The Scholars attended Breakfast at Lasker, an intimate gathering of the 2019 Lasker Laureates moderated by Jordan Gutterman, M.D. The breakfast provided a roundtable discussion for the group to ask questions ranging from career paths, making new discoveries, and how their discoveries are impacting human health today.
Gavi, the Vaccine Alliance, CEO Dr. Seth Berkley, discussed with the breakfast attendees the essential aspect of their mission: empowering the countries with which they work. He shared that this was not something science has included in the past but, by doing so, allows these countries’ people to have an even greater impact. Lasker Laureate Dr. Max Cooper shared that it is not always clear whether or not a research question has the potential for medical impact. However, he advised that researchers should follow their interests because many clinical advances started from curiosity driven research. Throughout the course of the roundtable discussion, each of the laureates gave thoughtful responses to questions posed by the group and provided some very personal insights and pearls of wisdom.
Following breakfast, the Scholars took photographs with the 2019 winners and attended a reception that included current and past Lasker Laureates, as well as renowned scientists and notable guests arriving to attend the awards ceremony.
The Lasker Basic Research Award honored Max D. Cooper of the Emory School of Medicine and Jacques F.A.P. Miller of The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia, for their discovery of the two distinct classes of lymphocytes, β and T cells, an achievement that provided the organizing principle of the adaptive immune system. Their pioneering and historic work over fifty years ago launched the course of modern immunology, inspiring major advances in basic and medical science.
The Lasker-DeBakey Clinical Research Award honored H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich for their invention of Herceptin, the first monoclonal antibody that blocks a cancer-causing protein, and for its development as a life-saving therapy for women with breast cancer. Shepard, currently with BetterOutcomes4Cancer, and Slamon, now at Max Planck Institute of Biochemisry, Martinsried, Germany, did their Herceptin work at Genentech. Slamon’s research was conducted at the University of California, Los Angeles, where he continues to work. The influence and impact of the Herceptin story extends beyond the development of a major new therapy. For example, stratifying patients based on expression/amplification of a gene and using a monoclonal antibody to block a cancer-causing protein are now being applied to other proteins in other cancers as well.
The Lasker-Bloomberg Public Science Award honored Gavi, the Vaccine Alliance, for providing sustained access to childhood vaccines around the globe, saving millions of lives, and for highlighting the power of immunization to prevent disease. Gavi is a public-private global partnership that brings together the World Health Organization, UNICEF, the World Bank, the vaccine industry, the Bill & Melinda Gates Foundation, and several other philanthropic organizations. Thanks to Gavi, more than 600 million children in 73 of the poorest countries have been vaccinated, with an estimated 8 million deaths averted. Over the last 16 years, Gavi has raised global immunization rates by bringing vaccines available to developing countries, by financially supporting the development of new vaccines, and by building stronger health care systems.
For full descriptive information on the 2019 Lasker Award winners, video viewing of award overviews, and expectance speeches, please visit: The Lasker Foundation. We gratefully thank the Albert and Mary Lasker Foundation for the opportunity to allow the Scholars to attend the prestigious Lasker Awards.
The Alliance aims to bring together Scholars of the NIH Oxford-Cambridge/Wellcome Trust Programme with leading academics, entrepreneurs, financiers, policy makers, and practitioners to help solve the problems that are highly relevant to society. Each year, six Scholars are invited to New York City to attend career development field trips leading up to the Lasker Awards.
A visit to Regeneron provided the Scholars with an opportunity to visualize, experience, and discuss careers in industry. The Scholars were introduced to the post-doc program at Regeneron and learned about their exciting projects and collaborations. Each of the Scholars prepared short presentations, which provided the scientists at Regeneron insight into the exciting work being done at the NIH, Oxford, Cambridge, and the University of Manchester. After the presentations, the Scholars were invited to have lunch with scientists and were given the opportunity to meet one-on-one with scientists of their choice. “I had a one-on-one with Dr. Andrew Murphy who is the EVP of Research,” explained Scholar Samuel Katz. “I wanted to ask him about some projects he was on and get his feedback on some ideas I’ve been thinking about. It was a very interesting discussion, I completely forgot to eat!” Scholar Daniel Bronder also met with Regeneron scientists over lunch and stated, “I particularly enjoyed meeting Drs. Crawford and Gurer over lunch and gaining more insights on their respective science. It was really cool to read their papers and then sit down with them to have a conversation.”
Following lunch, the Scholars toured Regeneron’s facilities and learned about the technology they use. Scholar Audrey Winkelsas learned that the Regeneron Genetics Center is generating four to five terabytes of data per day and sequencing approximately 10,000-15,000 exomes per week! They viewed robotized laboratories, challenging their thoughts about what science looks like when tasks such as pipetting and plating are automated. These automations create datasets which facilitate bioinformaticians’ pipelines. The Scholars listened in on a very diverse set of scientific talks, including one about a potential treatment for cardiovascular conditions and one on the response to the Ebola virus outbreak. “The trip to Regeneron was an insightful look into what science in industry really was like. It was refreshing to hear from the representatives how the driving force behind their innovation was not profit, but the science. This definitely broke down some of the preconceived notions I had about working in biotech, and everyone we met was very welcoming and seemed very happy to be working there,” stated Scholar Jessica van Loben Sels.
The following day, the Scholars visited Arsenal Capital Partners. The goal of this visit was to provide the Scholars with a bettering understanding of the role of business and specifically private equity investments in the healthcare sector. Scholars gained an understanding of how Arsenal invests in outsourced business service companies that focused on biopharmaceutical research, development and commercialization, and services to providers and payors with an aim towards improving efficiency and reducing costs. “The visit to Arsenal capital provided a unique introduction to the role of private equity in healthcare and biotech, which I had no previous exposure to. It was very interesting to hear the partners discuss the mission of Arsenal capital in improving healthcare and has created for me a newfound curiosity about private equity,” remarked Scholar Andrei Ramirez-Valdez.
The Scholars presented their research to a group of pharmaceutical executives, healthcare investors, and Alliance Board Directors. Scholar Kathleen Bashant-Day stated that “this was an opportunity to pitch our research in a setting that we hadn’t before been exposed to. It was interesting to see how business-minded people approach science and gratifying that they were excited about what we are doing.”
That evening, the Scholars were the guests of honor at a cocktail reception held in the home of Alliance board member Ann W. Jackson. Guests included individuals representing science, business, academia, private industry, philanthropy, the Lasker Foundation, and their 2019 essay contest winners, as well as New York City area alumni and NIH OxCam program faculty.
We gratefully thank Dr. George D. Yancopoulos and his colleagues at Regeneron, Arsenal Capital Partners, and with the supporters of the International Biomedical Research Alliance for their contributions to the experiences and events that provided an invaluable visit to New York for the Scholars.
BioHealth Innovation (BHI) Founder, President & CEO, Richard Bendis, hosts the BioTalk Podcast — conversations from the BioHealth Capital Region with some of the most accomplished and exciting business, academic, and government leaders in the biohealth industry. This episode, Mr. Bendis interviewed Dr. Michael Lenardo, co-founder of the NIH Oxford-Cambridge Scholars Program. In this Podcast, you will learn more about the National Institutes of Health, Dr. Lenardo’s research at the National Institute of Allergy and Infectious Diseases, and the impetus for starting the NIH Oxford-Cambridge Scholars Program.
